Led · Grant · Mar 2026

Antheia is a biosynthesis company focused on transforming pharmaceutical manufacturing through engineered microorganisms that produce complex active pharmaceutical ingredients (APIs). The firm employs its advanced biosynthesis platform to generate critical drug ingredients domestically, reducing reliance on fragile global supply chains. Under an ongoing collaboration with the U.S. government’s BioMaP-Consortium, Antheia will scale commercial production of two essential pharmaceutical compounds in the United States. The company positions its technology as a solution to longstanding vulnerabilities in healthcare supply chains and aims to build a more resilient, on-shore source of medicines for the American market. To date, Antheia has secured $21 million in federal project investment dedicated to this initiative, including a recent $9 million expansion award. These funds will be deployed to increase manufacturing capacity and accelerate the company’s path to large-scale commercialization. No additional operating metrics or revenue figures were disclosed in the article.

Led · Grant · Oct 2024

Resilience is a technology-driven contract development and manufacturing organization (CDMO) that partners with biopharma innovators to bring biologics, cell-based therapies, and other complex medicines to market more efficiently. The company is actively expanding a North American manufacturing network with end-to-end capabilities in sterile injectable production, device assembly, and packaging. Its Cincinnati site is undergoing a major build-out that is expected to become one of the continent’s largest and most advanced sterile injectable operations, while its Toronto facility anchors additional growth. Resilience positions itself to meet rising demand for on-shoring and reliable supply of advanced therapeutics. The firm has recently strengthened its balance sheet by resolving lease obligations tied to underutilized sites, improving overall operational efficiency. The newly secured long-term capital will fund continued facility expansion and help the company serve customers with greater stability and scale.

Led · Grant · Aug 2022

Nob Hill Therapeutics is a respiratory-focused healthcare company developing high-dose lung delivery technologies and therapeutics. It holds a patented Dry Powder Nebulizer platform that generates drug aerosols and delivers them to the lower respiratory tract independent of patient lung capacity. The company's patent-protected inhalation device can deliver high therapeutic doses directly to the lung and is designed for patients of all ages, including those with compromised lung function. Led by CEO Noel Greenberger and based in Albuquerque, NM, NHT plans to advance its technology and therapeutics toward regulatory milestones. The company recently raised $3M in Series A financing to fund continued development of its high-dose respiratory technology and pre-IND studies. Nob Hill Therapeutics is developing a patent‑protected DryNeb dry powder nebulizer platform designed to deliver high therapeutic doses directly to the lower respiratory tract. The device is intended to be suitable for patients of all ages and inhalation capabilities and is claimed to generate highly efficient drug aerosols independent of lung capacity. The company is using the platform to develop inhaled anti‑infective therapies, including an inhaled treatment for lung fungal infection. NHT was awarded an HHS Phase II SBIR grant of up to $1.73M to fund drug powder formulation, DryNeb device development, and other pre‑IND studies. This Phase II award builds on a successful Phase I grant and encouraging animal efficacy results reported the prior year. NHT is a VIC Technology Venture Development portfolio company and recently appointed Noel Greenberger as CEO effective September 1, 2022. The company is based in Albuquerque, N.M.

Led · Equity · Oct 2020

Cue Health makes the Cue Health Monitoring System, a reusable cartridge reader and single-use test kit that connects to a mobile app to deliver molecular diagnostic results in about 20 minutes. Its first commercially deployed assay detects SARS-CoV-2 RNA from a lower-nasal swab and received FDA Emergency Use Authorization in June. The company is also developing at-home influenza tests and intends to broaden its menu to other infectious diseases. With newly secured government funding, Cue plans to reach a production capacity of 100,000 tests per day and supply six million COVID-19 tests by March. The platform’s real-time, connected design aims to give individuals greater control over their health data and enable rapid public-health response. Financially, Cue recently raised a $100 million Series C round to expand manufacturing and test development, and has long-standing support from BARDA for its flu and COVID-19 programs. The latest capital infusion positions the San Diego-based company to scale manufacturing infrastructure and gain a higher profile in the competitive rapid diagnostics market.